Phase I Study of SF1126 for Patients With Relapsed or Refractory Neuroblastoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs SF 1126 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 21 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Aug 2015 According to a SignalRx Pharmaceuticals Inc media release, the first pediatric cancer patient has been dosed in this trial.